GlassScriptPhysician profile
Sarah Quinn
NPI 1891126512
$1,787.68
in general payments reported to CMS, 2019-2025
24 companies · $46.67 in 2025
The $46.67 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $475 · 2022: $504 · 2023: $197 · 2024: $565 · 2025: $46.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $363.75 | 2021-2023 | Veltassa |
| Amgen INC. | $358.79 | 2021-2025 | Aranesp, Parsabiv, Krystexxa |
| Glaxosmithkline, LLC. | $222.58 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $198.30 | 2022-2024 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $108.03 | 2023-2024 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.51 | 2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $62.10 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $47.59 | 2024-2025 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $33.23 | 2022 | |
| Fresenius USA Marketing, INC. | $25.95 | 2022-2023 | |
| Travere Therapeutics, INC. | $25.91 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.19 | 2023 | |
| Abbott Laboratories | $24.14 | 2021 | |
| Horizon Therapeutics Plc | $23.82 | 2023 | Krystexxa |
| Inspire Medical Systems, INC. | $22.55 | 2024 | Inspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $21.67 | 2021 | |
| Aurinia Pharma U.S., INC. | $19.57 | 2022 | |
| Daiichi Sankyo INC. | $19.43 | 2022 | |
| Chiesi USA, INC. | $18.80 | 2023 | Elfabrio |
| Alnylam Pharmaceuticals INC. | $18.45 | 2022 | |
| Opko Pharmaceuticals, LLC | $14.67 | 2021 | |
| Corcept Therapeutics | $14.57 | 2024 | Korlym |
| Ucb, INC. | $14.08 | 2024 | Bimzelx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.